Related Experiment Videos
Blood coagulation changes in liver disease
I A al Mofleh1, F Z al Faleh, A Allam
1Department of Medicine, College of Medicine, Riyadh, Kingdom of Saudi Arabia.
Insights
In liver disease patients, Anti-thrombin III (AT III) levels were significantly reduced more often than prothrombin time (PT) or fibrin polymerization curve (FPC) abnormalities. AT III is a more sensitive indicator of hepatocellular dysfunction.
Area of Science:
- Hepatology
- Hematology
- Clinical Biochemistry
Background:
- Liver disease significantly impacts coagulation factor synthesis and function.
- Assessing hepatocellular dysfunction requires sensitive and specific diagnostic markers.
Purpose of the Study:
- To compare the sensitivity of prothrombin time (PT), Anti-thrombin III (AT III), and fibrin polymerization curve (FPC) in evaluating liver disease severity.
- To determine the most effective coagulation parameter for assessing hepatocellular dysfunction.
Main Methods:
- Simultaneous measurement of PT, AT III levels, and FPC in patients with liver disease.
- Patients were categorized into two groups: cirrhosis (n=37) and miscellaneous liver disease (n=35).
Main Results:
- Significant PT prolongation observed in 82% of cirrhotics vs. 17% of miscellaneous liver disease patients.
- Significant AT III reduction noted in 94% of cirrhotics vs. 31% of miscellaneous liver disease patients.
- Abnormal FPC observed in 88% of cirrhotics vs. 32% of miscellaneous liver disease patients. Good correlation between PT and AT III levels.
Conclusions:
- Anti-thrombin III (AT III) measurement is a more sensitive indicator of hepatocellular dysfunction than PT or FPC.
- AT III levels provide a more comprehensive assessment of coagulation abnormalities in liver disease.
Abstract:
The study describes the results of prothrombin time (PT), Anti-thrombin III (AT III) and fibrin polymerization curve (FPC) measured simultaneously in patients with liver disease who were divided into two groups: cirrhotics (n = 37) and miscellaneous liver disease (n = 35). There was significant prolongation of PT in 82% of cirrhotics and in 17% of the miscellaneous liver disease group. In contrast significant reduction of AT III levels was noted in 94% of cirrhotics and 31% of the miscellaneous liver disease group. Abnormal FPC was seen in 88% and 32% respectively. There was a good correlation between PT and AT III levels. It was concluded that AT III measurement is a more sensitive indicator than PT and FPC in the assessment of hepatocellular dysfunction.